Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bromopride→

Bromopride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
4093-35-0
Molecular formula
C14H22BrN3O2
Molecular weight
344.25 g/mol
Drug class
Substituted benzamide antiemetic and prokineticdopamine D2-receptor antagonist
Mechanism of action
Antagonises dopamine D2 receptors in the chemoreceptor trigger zone and gastrointestinal tract, reducing emetic signalling and facilitating upper gastrointestinal motility. Experimental data also report 5-HT4-receptor agonist effects in isolated human atrial tissue; their clinical relevance to its GI use is not established.
Indications / reported uses
  • Nausea and vomiting
  • Functional dyspepsia and selected upper gastrointestinal motility disorders in countries where bromopride is authorised; approved indications and formulations vary by jurisdiction

Sources: Peer-reviewed pharmacology study (2025) · Peer-reviewed clinical review · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bromopride Environmental Risk Assessment (ERA) (the Bromopride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.